Haleon PLC Sponsored ADR (NYSE:HLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, three have assigned a buy recommendation and two have assigned a strong buy recommendation to the company.

Several research firms have recently weighed in on HLN. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Finally, Rothschild & Co Redburn lowered Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th.

Haleon Stock Down 0.0%

Haleon stock opened at $10.10 on Wednesday. The firm has a market cap of $44.46 billion, a price-to-earnings ratio of 25.88, a PEG ratio of 2.33 and a beta of 0.13. Haleon has a 52-week low of $8.65 and a 52-week high of $11.28. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The firm has a 50 day moving average price of $9.27 and a two-hundred day moving average price of $9.86.

Hedge Funds Weigh In On Haleon

Several institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC bought a new stake in shares of Haleon in the 4th quarter valued at $187,000. AQR Capital Management LLC grew its holdings in Haleon by 22.5% in the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after purchasing an additional 17,720 shares during the period. Focus Partners Wealth increased its stake in Haleon by 7.6% in the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after purchasing an additional 5,178 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares in the last quarter. Finally, CW Advisors LLC raised its holdings in shares of Haleon by 11.6% during the second quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after purchasing an additional 2,601 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.